MGX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Metagenomi Therapeutics Inc (MGX) is not a strong buy at the moment for a beginner investor with a long-term strategy. The lack of positive catalysts, weak financial performance, and hedge fund selling trends suggest limited upside potential in the near term. While technical indicators are neutral, no significant signals or events justify immediate investment.
The MACD histogram is positive but contracting, RSI is neutral at 48.078, and moving averages are converging, indicating no clear trend. The stock is trading below the pivot level of 1.616, with key support at 1.469 and resistance at 1.763.
No significant positive catalysts identified. Insiders are neutral, and there is no recent news or congress trading activity.
Hedge funds are selling heavily, with a 323.12% increase in selling over the last quarter. Financial performance shows declining revenue (-24.80% YoY) and negative net income, despite slight improvements in EPS and net income percentage.
In Q3 2025, revenue dropped by -24.80% YoY to $8,659,000. Net income improved slightly but remains negative at -$20,393,000. EPS increased to -0.55 (+7.84% YoY), and gross margin remained stable at 100%. Overall, financials indicate weak growth.
No analyst rating or price target changes available for MGX.
